IceCure Medical Ltd. (ICCM) Form 6-K — Oct 13, 2026
IceCure Medical announced that its ProSense breast cancer cryoablation system was featured in two key scientific sessions, two workshops and two posters at the EUSOBI 2026 Annual Scientific Meeting in Maastricht. Presented 12-month clinical data showed objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation alone. ProSense remains the only FDA-cleared device for local treatment of breast cancer in patients 70+ with low-risk tumors ≤1.5 cm on adjuvant endocrine therapy.
Key figures
- Clinical workshops
- 2
- Scientific posters
- 2
- Key scientific sessions
- 2
- Workshop participants each
- nearly 70
- Objective response rate cryo alone
- 91.7% (24 patients, 12-month data)
- Objective response rate cryo plus endocrine therapy
- 97.5% (40 patients, 12-month data)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.